Grants
Additional funding opportunities
Research Funding Opportunities
Grants Awarded for Health Sciences Research
| Title | Type | $ Amount | Activity | Investigator | Unit |
Sponsor |
Date |
|---|---|---|---|---|---|---|---|
| Effect of Myostatin Inhibition on Muscle Size and Muscle Function in a Novel Mouse Model of Typical Nemaline Myopathy | Grant | $124,635.00 | Research | Hendrikus Granzier | Cellular & Molecular Medicine | A Foundation Building Strength | 12/2020 |
| Percutaneous or Surgical Mitral Valve REpair in PAtients with PrImaRy Mitral Regurgitation Whose Mitral Valve has been Determined to be suitable for correction by MV repair Surgery (REPAIR MR) | Contract | $230,208.00 | Clinical Trial | Marvin Eng | COM Phx Internal Medicine | Abbott Laboratories | 12/2021 |
| Clinical TRIal to EvaLUate Cardiovascular OutcoMes IN PAtients Treated with the Tricuspid ValvE Repair System Pivotal (TRILUMINATE Pivotal) | Contract | $184,057.72 | Clinical Trial | Divya Verma | COM Phx Internal Medicine | Abbott Laboratories | 03/2021 |
| Dorsal spInal cord STImulatioN vs mediCal management for the Treatment of low back pain (DISTINCT) | Contract | $545,762.00 | Clinical Trial | Mohab Ibrahim | Anesthesiology | Abbott Laboratories | 03/2021 |
| A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14)-Positive Relapsed or Refractory Multiple... | Contract | $392,700.50 | Clinical Trial | Krisstina Gowin | Cancer Center Division | AbbVie Incorporated | 07/2020 |
| A Phase 1b, Dose Escalation and Expansion Study of Lemzoparlimab (TJ011133) With or Without Dexamethasone and in Combination With Anti-Myeloma Regimens for the Treatment of Patients With Relapsed/Refr | Contract | $1,799,212.70 | Clinical Trial | Muhammad Husnain | Cancer Center Division | AbbVie Incorporated | 01/2022 |
| A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-Tumor Activity of ABBV-321 in Subjects with Advanced Solid Tumors Associated with Overexpression of the Epidermal Growth Factor Recept | Contract | $854,975.00 | Clinical Trial | Hani Babiker | Cancer Center Division | AbbVie Incorporated | 10/2020 |
| Phase 3b Study for Evaluation of Efficacy and Nutritional Benefits of Pancrelipase in Patients with Exocrine Pancreatic Insufficiency due to Periampullary and Pancreatic Cancer | Contract | $122,409.40 | Clinical Trial | Hani Babiker | Cancer Center Division | AbbVie Incorporated | 01/2020 |
| CREON (Pancrelipase) Therapy for Subjects with Exocrine Pancreatic Insufficiency (EPI) due to Pancreatic Cancer: A Double-Blind, Randomized, Parallel Design with 2 Dose Cohorts of Pancrelipase... | Contract | $117,787.55 | Clinical Trial | Jen-Jung Pan | COM Phx Internal Medicine | AbbVie Incorporated | 08/2020 |
| Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial | Contract | $113,035.00 | Clinical Trial | Deepak Acharya | Sarver Heart Center | ABIOMED, Inc. | 08/2020 |
| Alternative Anticoagulant and Biocompatibility Study & Heparin-Impella Surface Interaction with Heparin-Containing Purge Solutions | Contract | $288,559.00 | Research | Marvin Slepian | UAHS Research | ABIOMED, Inc. | 11/2020 |
| Independent Hemocompatibility Assessment of ABIOMED Mechanical Circulatory Support Devices: Hemolysis and Platelet Activation Studies | Contract | $600,000.00 | Research | Marvin Slepian | UAHS Research | ABIOMED, Inc. | 02/2022 |
| Applied Research to Address the Coronavirus (COVID-19) Emerging Public Health Emergency | Contract | $10,000.00 | Research | Jefferey Burgess | Community Environment & Policy | Abt Associates | 05/2020 |
| Phase II Pilot Study of FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-Type, Left-Sided Colorectal Cancer | Contract | $127,173.74 | Clinical Trial | Aaron Scott | Cancer Center Division | Academic Gastrointestinal Cancer Consortium | 03/2020 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy fo | Contract | $989,638.00 | Clinical Trial | Franz Rischard | Medicine | Acceleron Pharmaceuticals | 01/2022 |
| A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-r | Contract | $930,117.52 | Clinical Trial | Franz Rischard | Medicine | Acceleron Pharmaceuticals | 02/2022 |
| An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH | Contract | $447,126.32 | Clinical Trial | Franz Rischard | Medicine | Acceleron Pharmaceuticals | 01/2022 |
| A Phase 2, Double-blind, Randomized, Placebocontrolled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension( | Contract | $2,048,686.48 | Clinical Trial | Franz Rischard | Medicine | Acceleron Pharmaceuticals | 04/2022 |
| AcQMap Pulmonary Vein Isolation Plus Left Atrial Slow Zone Mapping and Ablation (PLASZMA) | Contract | $158,922.40 | Clinical Trial | Jonathan Weiss | COM Phx Internal Medicine | Acutus Medical, Inc. | 03/2021 |
| AcQMap US Registry of Procedural and Long-term Clinical Outcomes (Discover-US) | Contract | $59,455.52 | Clinical Trial | Wilber Su | COM Phx Internal Medicine | Acutus Medical, Inc. | 03/2021 |
| iCLAS for Persistent Atrial Fibrillation | Contract | $193,319.94 | Clinical Trial | Wilber Su | COM Phx Internal Medicine | Adagio Medical, Inc | 02/2021 |
| Enhancing the Public Health Workforce with the Skills and Resources to Provide Culturally Responsive Services for Individuals with Developmental Disabilities in Arizona | Grant | $113,670.00 | Other Sponsored Activity | Wendy Parent-Johnson | Family and Community Medicine | Administration for Community Living | 04/2022 |
| Finds Their Way: Communities for Youth Transition | Grant | $223,385.00 | Other Sponsored Activity | Wendy Parent-Johnson | Family and Community Medicine | Administration for Community Living | 11/2021 |
| Increasing COVID Vaccines for the People with Disabilities and Underserved Communities | Grant | $59,701.00 | Research Training | Wendy Parent-Johnson | Family and Community Medicine | Administration for Community Living | 05/2021 |
| Sonoran University Center for Excellence in Developmental Disabilities (UCEDD) | Grant | $577,449.00 | Research Training | Wendy Parent-Johnson | Family and Community Medicine | Administration for Community Living | 08/2021 |